Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pusan National University Hospital
This is a prospective, single-arm, open-label study to assess evaluate the relevance of intratumoral washing by ultrathin bronchoscopy (outer diameter; 3mm) for detection of EGFR mutation (including T790M positivity) using cobas real-time PCR and droplet digital PCR (DDPCR) in patients with NSCLC.
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 20 years
Obtained written informed consent
Patients diagnosed with NSCLC by histology or cytology and inoperable stage IV at the time of study enrollment
Patients with the following EGFR gene mutations: E19Del, L858R alone or concurrent rare EGFR gene mutations (T790M, G719X, exon 20 insertion, S768I)
Patients previously treated with EGFR-TKIs such as gefitinib, erlotinib, afatinib, dacomitinib as first line therapy
Patients who had shown clinical benefits (CR, PR, SD) from EGFR-TKIs and had been confirmed PD on those therapy according to RECIST v 1.1.
Patients who underwent liquid biopsy (plasma) for EGFR mutation at the time of PD on EGFR-TKIs
Patients who plan to undergo tissue biopsy for EGFR mutation at the time of PD on EGFR-TKIs
You may not be if
Patients who withdraw informed consent
Patients who are unable to undergo liquid biopsy (plasma) and tissue biopsy for EGFR mutation based on the investigator's judgement
Clareo Health | Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer
